Nuclera
Benchtop eProtein Discovery system that lets labs express and characterise proteins in days rather than months.
- Biotech & Life Sciences
- Series B+
- Cambridge
- Sector
- Biotech & Life Sciences
- Stage
- Series B+
- Based in
- Cambridge
- Founded
- 2013
- Funding raised
- $87m Series C (2024–2026); earlier round
- Website
- nuclera.com
Nuclera builds the eProtein Discovery system, a benchtop instrument and cartridge platform that lets researchers screen, express and purify proteins in their own lab within days, replacing lengthy outsourced workflows. The Cambridge company was started in 2013 by University of Cambridge PhD students Michael Chen and Gordon McInroy and serves pharmaceutical, biotech and academic groups working on drug discovery. Nuclera closed a $75m Series C in 2024 and extended it by $12m in January 2026, taking the round to $87m, led by Elevage Medical Technologies and Jonathan Milner with the British Business Bank and GK Goh. Recent milestones include a membrane protein workflow, a Cytiva collaboration and the first CRO installation at Domainex.
Team
- Michael Chen, Co-founder & CEO
- Gordon McInroy, Co-founder
Backed by
More startups in the directory
Yoto
Screen-free audio player and card library giving children control of stories, music and podcasts.
Truelayer
Open banking platform providing account-to-account payments and financial data APIs for businesses across Europe.
Numan
Digital health service offering weight-loss, men's health and preventive care programmes.
Lightyear
Low-cost multi-currency investing app offering stocks, ETFs and savings across 25 European countries.
LemFi
Remittance and financial services app for immigrants sending money home.
HIVED
All-electric parcel delivery network serving retailers in London and the South East.
Subscribe to Newsletter
UK startup news, founder stories and funding insight, straight to your inbox every week. Free.